Processa Net Receivables from 2010 to 2026
| PCSA Stock | USD 2.10 0.28 11.76% |
Net Receivables | First Reported 2012-09-30 | Previous Quarter 70.3 K | Current Value 22.3 K | Quarterly Volatility 47.9 K |
Check Processa Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Processa Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 99.5 K, Selling General Administrative of 3 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 198, Dividend Yield of 0.0 or PTB Ratio of 1.74. Processa financial statements analysis is a perfect complement when working with Processa Pharmaceuticals Valuation or Volatility modules.
Processa | Net Receivables | Build AI portfolio with Processa Stock |
Analyzing Processa Pharmaceuticals's Net Receivables over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Receivables has evolved provides context for assessing Processa Pharmaceuticals's current valuation and future prospects.
Latest Processa Pharmaceuticals' Net Receivables Growth Pattern
Below is the plot of the Net Receivables of Processa Pharmaceuticals over the last few years. It is Processa Pharmaceuticals' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Processa Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Receivables | 10 Years Trend |
|
Net Receivables |
| Timeline |
Processa Net Receivables Regression Statistics
| Arithmetic Mean | 68,619 | |
| Geometric Mean | 40,787 | |
| Coefficient Of Variation | 97.20 | |
| Mean Deviation | 40,598 | |
| Median | 62,709 | |
| Standard Deviation | 66,696 | |
| Sample Variance | 4.4B | |
| Range | 230.4K | |
| R-Value | 0.41 | |
| Mean Square Error | 3.9B | |
| R-Squared | 0.17 | |
| Significance | 0.10 | |
| Slope | 5,428 | |
| Total Sum of Squares | 71.2B |
Processa Net Receivables History
About Processa Pharmaceuticals Financial Statements
Processa Pharmaceuticals stakeholders use historical fundamental indicators, such as Processa Pharmaceuticals' Net Receivables, to determine how well the company is positioned to perform in the future. Although Processa Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Processa Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Processa Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Processa Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Receivables | 80.8 K | 61.4 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Processa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Processa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Processa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Processa Pharmaceuticals Stock:Check out the analysis of Processa Pharmaceuticals Correlation against competitors. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. Anticipated expansion of Processa directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Processa Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Processa Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Processa Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Processa Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between Processa Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Processa Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Processa Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.